London: Scientists have devised a new test that can identify gene defects in cancer patients, which they claim may pave the way for each patient getting "personalised" medicine.
An international team, led by Harvard Medical School, says the `Snapshot` test screens patients for mutations in 14key cancer genes at the same time. The test, which examines tissue taken from tumours, gives a result within three weeks.
By this time, patients have had surgery and can then be offered the most effective drugs to target the mutations fuelling their specific cancer, say the scientists.
In their research the scientists say that in as many as one in 10 cases, they have discovered mutations which would normally have been "invisible" resulting in patients getting treatment that might not work, the `Daily Mail` reported.
Dr Dora Dias-Santagata at Massachusetts General Hospital, a team member, said: "This test allows us to look for a defined set of common mutations that occur in cancer cells, but not in the other cells of the body.
"These mutations affect genes that disrupt the checks and balances that usually govern the behaviour of normal cells, giving the mutant cells an advantage to divide and multiply, and the potential to give rise to a tumour.
"Because each tumour will harbour a specific set of mutations, the Snapshot test allows to match individual patients with the therapies that will most likely be effective in treating their cancer."
In fact, in their research of almost 600 patients with lung cancer, the scientists analysed samples of tumour tissue for 50 "hotspots" -- genetic mutations in 14 key cancer genes.
The average turnaround time from a sample being sent for testing to final results was just 2.8 weeks. The genes include those such as EGFR, KRAS, BRAF, HER2, and half of the samples tested positive for one or more mutations.
Previously, testing could only be carried out on a handful of genetic mutations at the same time.
Dr Lecia Sequist, who led the team, said: "Our study is exciting as it demonstrates that indeed it is possible today to integrate testing for multiple genetic biomarkers into a busy clinic and steer patients toward personalised therapies."
The study found that 10 per cent of patients harboured genetic abnormalities that would not have been found with a less comprehensive test, and remained "invisible", according to findings published in the `Annals of Oncology` journal.
PTI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.